RU2397176C2 - Стероидные фармацевтические продукты, направленные на спираль 12 - Google Patents
Стероидные фармацевтические продукты, направленные на спираль 12 Download PDFInfo
- Publication number
- RU2397176C2 RU2397176C2 RU2006128574/04A RU2006128574A RU2397176C2 RU 2397176 C2 RU2397176 C2 RU 2397176C2 RU 2006128574/04 A RU2006128574/04 A RU 2006128574/04A RU 2006128574 A RU2006128574 A RU 2006128574A RU 2397176 C2 RU2397176 C2 RU 2397176C2
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- reductase
- dehydrogenase
- group
- type
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 210000001519 tissue Anatomy 0.000 claims abstract 6
- 239000003098 androgen Substances 0.000 claims abstract 4
- 230000002280 anti-androgenic effect Effects 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract 2
- 206010020112 Hirsutism Diseases 0.000 claims abstract 2
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 206010039792 Seborrhoea Diseases 0.000 claims abstract 2
- 206010000496 acne Diseases 0.000 claims abstract 2
- 230000000638 stimulation Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 27
- 239000003112 inhibitor Substances 0.000 claims 24
- 210000002307 prostate Anatomy 0.000 claims 16
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 15
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 15
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 claims 13
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 claims 13
- 229940124139 Hydroxysteroid dehydrogenase inhibitor Drugs 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 101000640362 Arabidopsis thaliana (+)-neomenthol dehydrogenase Proteins 0.000 claims 11
- 101000640360 Papaver somniferum Noscapine synthase SDR1 Proteins 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 claims 3
- 108010065942 Prostaglandin-F synthase Proteins 0.000 claims 3
- 229940123934 Reductase inhibitor Drugs 0.000 claims 3
- 101710142587 Short-chain dehydrogenase/reductase Proteins 0.000 claims 3
- 230000001548 androgenic effect Effects 0.000 claims 3
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 2
- 125000001174 sulfone group Chemical group 0.000 claims 2
- 125000003375 sulfoxide group Chemical group 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 claims 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- 102100037843 Dehydrogenase/reductase SDR family member 1 Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 101000806152 Homo sapiens Dehydrogenase/reductase SDR family member 1 Proteins 0.000 claims 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 1
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 claims 1
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 1
- 210000000579 abdominal fat Anatomy 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- -1 chloro, bromo, iodo Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000036642 wellbeing Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 3
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- GAFBZBJMRSLRPM-UHFFFAOYSA-N CC(C)CN1C(C)CCCC1 Chemical compound CC(C)CN1C(C)CCCC1 GAFBZBJMRSLRPM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53512104P | 2004-01-07 | 2004-01-07 | |
| US60/535,121 | 2004-01-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006128574A RU2006128574A (ru) | 2008-02-20 |
| RU2397176C2 true RU2397176C2 (ru) | 2010-08-20 |
Family
ID=34749018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006128574/04A RU2397176C2 (ru) | 2004-01-07 | 2005-01-06 | Стероидные фармацевтические продукты, направленные на спираль 12 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9090651B2 (fr) |
| EP (1) | EP1704161A4 (fr) |
| JP (1) | JP4866740B2 (fr) |
| KR (2) | KR101536701B1 (fr) |
| CN (2) | CN102358750B (fr) |
| AU (2) | AU2005203922A1 (fr) |
| BR (1) | BRPI0506470A (fr) |
| CA (1) | CA2551737C (fr) |
| IL (1) | IL176538A0 (fr) |
| MY (1) | MY157898A (fr) |
| NO (1) | NO20063564L (fr) |
| RU (1) | RU2397176C2 (fr) |
| TW (1) | TWI383993B (fr) |
| WO (1) | WO2005066194A1 (fr) |
| ZA (1) | ZA200605242B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101536701B1 (ko) | 2004-01-07 | 2015-07-14 | 앙도르쉐르슈 인코포레이티드 | 헬릭스 12 배향형 스테로이드계 약학 제품 |
| MX368189B (es) | 2004-10-20 | 2019-09-23 | Endorecherche Inc | Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas. |
| GB0428128D0 (en) * | 2004-12-22 | 2005-01-26 | Avecia Ltd | Process |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
| US8067448B2 (en) | 2008-02-22 | 2011-11-29 | Radius Health, Inc. | Selective androgen receptor modulators |
| US8268872B2 (en) * | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| US20090285893A1 (en) * | 2008-05-19 | 2009-11-19 | The Procter & Gamble Company | Treatment of heart failure in women |
| GB2461037A (en) * | 2008-06-17 | 2009-12-23 | Elias Bouras | A method of treating alopecia using a composition comprising a cardiac glycoside |
| EP2419400A1 (fr) | 2009-04-15 | 2012-02-22 | Research Triangle Institute | Inhibiteurs de la recapture des monoamines |
| MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
| SI2568806T1 (sl) | 2010-05-12 | 2016-09-30 | Radius Health, Inc. | Režimi zdravljenja |
| CA2799653A1 (fr) | 2010-06-04 | 2011-12-08 | Bertrand Leblond | Isoquinoleines substituees et leur utilisation en tant qu'inhibiteurs de polymerisation des tubulines |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| AU2011312490B2 (en) | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
| CN102746360B (zh) * | 2012-06-19 | 2014-07-02 | 广西民族大学 | 四种喜树碱-甾体缀合物的合成及其应用 |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| PT3122426T (pt) | 2014-03-28 | 2023-02-28 | Univ Duke | Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio |
| CN105237606B (zh) * | 2014-07-11 | 2018-08-24 | 上海创诺制药有限公司 | 一种用于合成去氧孕烯的中间体及其制备方法和应用 |
| CN105237605B (zh) * | 2014-07-11 | 2019-01-25 | 上海迪赛诺生物医药有限公司 | 一种用于合成孕二烯酮的中间体及其制备方法和应用 |
| EP3288383A4 (fr) | 2015-04-29 | 2019-01-23 | Radius Pharmaceuticals, Inc. | Méthodes de traitement du cancer |
| HRP20220619T1 (hr) | 2016-06-22 | 2023-02-03 | Ellipses Pharma Ltd | Postupci za liječenje ar+ raka dojke |
| ES2981967T3 (es) | 2017-01-05 | 2024-10-14 | Radius Pharmaceuticals Inc | Formas polimórficas de RAD1901-2HCl |
| CN108822175B (zh) * | 2018-04-26 | 2021-01-05 | 昆明理工大学 | 3,16-雄甾烯二酮类化合物及其应用 |
| JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形形態 |
| JOP20210218A1 (ar) | 2019-02-12 | 2023-01-30 | Radius Pharmaceuticals Inc | عمليات ومركبات |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068217A1 (fr) * | 2002-02-15 | 2003-08-21 | Endorecherche, Inc. | Derives biphenyle et leur utilisation comme agents anti-androgeniques |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| DE3333240A1 (de) | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| DE3761308D1 (de) * | 1986-07-23 | 1990-02-08 | Akzo Nv | 18-phenylestrane-derivate. |
| US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
| US5064654A (en) | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
| US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE69519368T2 (de) | 1994-01-06 | 2001-03-08 | Sri International, Menlo Park | Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| RU2000125533A (ru) | 1998-03-11 | 2002-10-20 | Эндорешерш, Инк. (Ca) | Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения |
| AU8821301A (en) | 2000-06-28 | 2002-01-08 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification, design and use |
| JP3908162B2 (ja) | 2000-06-30 | 2007-04-25 | 中外製薬株式会社 | 新規な抗アンドロゲン剤 |
| AU2002326823B2 (en) | 2001-09-06 | 2005-12-15 | Merck Sharp & Dohme Corp. | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| CA2478186C (fr) * | 2002-03-13 | 2011-08-23 | Merck & Co., Inc. | Derives de 4-azasteroide fluore en tant que modulateur de recepteur androgenique |
| US20050131005A1 (en) * | 2002-04-30 | 2005-06-16 | Jiabing Wang | 4-azasteroid derivatives as androgen receptor modulators |
| KR101536701B1 (ko) | 2004-01-07 | 2015-07-14 | 앙도르쉐르슈 인코포레이티드 | 헬릭스 12 배향형 스테로이드계 약학 제품 |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
-
2005
- 2005-01-06 KR KR1020067015954A patent/KR101536701B1/ko not_active Expired - Fee Related
- 2005-01-06 CA CA002551737A patent/CA2551737C/fr not_active Expired - Fee Related
- 2005-01-06 KR KR1020137024835A patent/KR20130124576A/ko not_active Ceased
- 2005-01-06 EP EP05700249A patent/EP1704161A4/fr not_active Withdrawn
- 2005-01-06 RU RU2006128574/04A patent/RU2397176C2/ru not_active IP Right Cessation
- 2005-01-06 WO PCT/CA2005/000011 patent/WO2005066194A1/fr not_active Ceased
- 2005-01-06 JP JP2006548053A patent/JP4866740B2/ja not_active Expired - Fee Related
- 2005-01-06 AU AU2005203922A patent/AU2005203922A1/en not_active Abandoned
- 2005-01-06 BR BRPI0506470-8A patent/BRPI0506470A/pt not_active IP Right Cessation
- 2005-01-06 CN CN201110251554.5A patent/CN102358750B/zh not_active Expired - Fee Related
- 2005-01-06 TW TW094100344A patent/TWI383993B/zh not_active IP Right Cessation
- 2005-01-06 CN CNA200580007350XA patent/CN1930181A/zh active Pending
- 2005-01-07 US US11/030,850 patent/US9090651B2/en active Active
- 2005-01-07 MY MYPI20050071A patent/MY157898A/en unknown
-
2006
- 2006-06-25 IL IL176538A patent/IL176538A0/en unknown
- 2006-06-26 ZA ZA200605242A patent/ZA200605242B/en unknown
- 2006-08-07 NO NO20063564A patent/NO20063564L/no not_active Application Discontinuation
-
2009
- 2009-05-22 AU AU2009202038A patent/AU2009202038A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068217A1 (fr) * | 2002-02-15 | 2003-08-21 | Endorecherche, Inc. | Derives biphenyle et leur utilisation comme agents anti-androgeniques |
Non-Patent Citations (1)
| Title |
|---|
| ISHOKA T. Et al // Bioorg.and Med. Chem. 2002, v.10, p.1555-1566. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005066194A1 (fr) | 2005-07-21 |
| JP2007519635A (ja) | 2007-07-19 |
| RU2006128574A (ru) | 2008-02-20 |
| AU2009202038A1 (en) | 2009-06-11 |
| EP1704161A1 (fr) | 2006-09-27 |
| TWI383993B (zh) | 2013-02-01 |
| JP4866740B2 (ja) | 2012-02-01 |
| CN102358750B (zh) | 2015-11-25 |
| TW200530264A (en) | 2005-09-16 |
| HK1167657A1 (zh) | 2012-12-07 |
| KR101536701B1 (ko) | 2015-07-14 |
| CA2551737A1 (fr) | 2005-07-21 |
| CN102358750A (zh) | 2012-02-22 |
| EP1704161A4 (fr) | 2011-06-08 |
| KR20070003851A (ko) | 2007-01-05 |
| NO20063564L (no) | 2006-10-09 |
| BRPI0506470A (pt) | 2007-02-21 |
| ZA200605242B (en) | 2007-10-31 |
| KR20130124576A (ko) | 2013-11-14 |
| AU2005203922A1 (en) | 2005-07-21 |
| US20050250749A1 (en) | 2005-11-10 |
| CN1930181A (zh) | 2007-03-14 |
| US9090651B2 (en) | 2015-07-28 |
| AU2009202038A2 (en) | 2009-08-06 |
| IL176538A0 (en) | 2006-10-05 |
| MY157898A (en) | 2016-08-15 |
| CA2551737C (fr) | 2009-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397176C2 (ru) | Стероидные фармацевтические продукты, направленные на спираль 12 | |
| RU2000125533A (ru) | Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения | |
| KR920703065A (ko) | 안드로겐 관련질병의 치료방법 | |
| CA2612398A1 (fr) | Antiandrogenes non-steroidiens a affinite pour le helix 12 | |
| US6423698B1 (en) | Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia | |
| Stoliar et al. | SCH 13521 in the treatment of advanced carcinoma of the prostate | |
| KR960704555A (ko) | 5-알파 환원효소 억제제를 사용한 안드로겐성 탄모증의 치료 방법(Method of treating androgenic alopecia with 5-alpha reductase inhibitors) | |
| IE902459A1 (en) | Combination therapy for the prophylaxis and/or treatment of¹benign prostatic hyperplasia | |
| KR950701527A (ko) | 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY) | |
| CA2933693C (fr) | Antiandrogenes non steroidiens et modulateurs de recepteur d'androgene selectifs avec un fragment pyridyle | |
| Cadilla et al. | Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential | |
| EP0863760B1 (fr) | Utilisation des composes antimineralocorticoides contre le syndrome de sevrage des narcotiques | |
| Brodie et al. | Aromatase inhibitors and their potential clinical significance | |
| Poirier | Recent patents on new steroid agents targeting the steroidogenesis for endocrine cancer treatments | |
| JP2006520780A5 (fr) | ||
| Gao et al. | Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor | |
| US20030134899A1 (en) | Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect | |
| Tindall et al. | Androgen antagonists in androgen target tissues | |
| EP1324754A1 (fr) | Combinaison pharmaceutique d'un anti-androgene et de tamoxifene pour obtenir un effet anti-androgenique et une inhibition d'aromatase | |
| Arya et al. | A Review of the Azasteroid-type 5-alpha Reductase Inhibitors for the Management of Benign Prostatic Hyperplasia | |
| Rasmusson | Chemical control of androgen action | |
| RU2000102642A (ru) | Лечебное средство против алопеции | |
| Nemane et al. | A Review on Finasteride: A 5-Alpha Reductase Inhibitors, Its Mechanism, Facts and Benefits | |
| US20030114519A1 (en) | Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition | |
| BE888277R (fr) | Preparations pharmaceutiques, |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170107 |